Cellular reprogramming for clinical cartilage repair

Britta J.H. Driessen · Colin Logie · Lucienne A. Vonk

Received: 29 August 2016 /Accepted: 17 January 2017 /Published online: 31 January 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract The repair of articular cartilage needs a sufficient number of chondrocytes to replace the defect tissue, and therefore, expansion of cells is generally required. Chondrocytes derived by cellular reprogramming may provide a solution to the limitations of current (stem) cell-based therapies. In this article, two distinct approaches—induced pluripotent stem cell (iPSC)-mediated reprogramming and direct lineage conversion—are analysed and compared according to criteria that encompass the qualification of the method and the derived chondrocytes for the purpose of clinical application. Progress in iPSC generation has provided insights into the replacement of reprogramming factors by small molecules and chemical compounds. As follows, multistage chondrogenic differentiation methods have shown to improve the chondrocyte yield and quality. Nevertheless, the iPSC ‘detour’ remains a time- and cost-consuming approach. Direct conversion of fibroblasts into chondrocytes provides a slight advantage over these aspects compared to the iPSC detour. However, the requirement of constitutive transgene expression to inhibit hypertrophic differentiation limits this approach of being translated to the clinic. It can be concluded that the quality of the derived chondrocytes highly depends on the characteristics of the reprogramming method and that this is important to keep in mind during the experimental set-up. Further research into both reprogramming approaches for clinical cartilage repair has to include proper control groups and epigenetic profiling to optimize the techniques and eventually derive functionally stable articular chondrocytes.

Keywords Articular cartilage · Clinical application · Direct lineage reprogramming · Induced pluripotent stem cells · Regenerative medicine

Abbreviations
AA2P Ascorbic acid 2-phosphate
ACAN Aggrecan
ACI Autologous chondrocyte implantation
BMP Bone morphogenetic protein
c-Myc Myelocytomatosis oncogene
COL2A1 Collagen type II alpha 1
DF Dermal fibroblasts
EB Embryoid body
ECM Extracellular matrix
EMT Epithelial-to-mesenchymal transition
ESC Embryonic stem cell
FBS Foetal bovine serum
FCM Flow cytometry
FGF-2 Fibroblast growth factor 2
GAG Glycosaminoglycan
GDF5 Growth and differentiation factor 5
Articular cartilage is a load-bearing, avascular tissue composed of chondrocytes embedded in an extracellular matrix (ECM) to form the basis of smooth articulation of the joint. Ageing and trauma are the main causes of cartilage degeneration, a common issue in the human population (Heidari 2011). During life, mechanical load on damaged joints can accelerate focal cartilage degeneration, eventually leading to the onset of osteoarthritis. The avascularity of cartilage and mitotically inactive chondrocytes limits the intrinsic healing capacity of the tissue.

Current therapies include microfracture (MFX) for relatively small defects (<2 cm²) (Trice et al. 2010) and autologous chondrocyte implantation (ACI) for larger defects. ACI, introduced by Brittberg et al. (1994), is the first clinical approved cell therapy that aims to regenerate functional cartilage (Brittberg et al. 1994). This therapy involves the harvest of chondrocytes from a low weight-bearing area followed by culture expansion to obtain sufficient cells and subsequent reinjection of the cells into the defect. Although the clinical outcome of ACI is satisfactory, the expansion of the chondrocytes affects chondrogenic quality and causes dedifferentiation, i.e. an up-regulation of type I collagen and down-regulation of type II collagen and aggrecan expression which often results in fibrocartilage as repair tissue (Ma et al. 2013a). Also, the intervention is expensive and it requires two surgeries which makes the therapy invasive. ACI is considered to be effective for cartilage defects ranging from 2 to 5 cm²; the restoration of defects larger than that remains a challenge (EMA 2014).

Nowadays, multipotent mesenchymal stem cells (MSCs) are the most well-studied stem cells because of their proliferative features, immunomodulatory characteristics and chondrogenic potential (Pittenger et al. 1999). Unfavourably, limitations of MSCs are the heterogeneity, limited chondrogenic capacity after expansion and age-related function decline (Ho et al. 2008; Lubis and Lubis 2012). Together with the invasive harvesting method and low cell yield, MSC-based cartilage regeneration could be substituted by other stem cell types. This has provided a window of opportunity for induced pluripotent stem cells (iPSCs) to enter the field of cartilage regeneration.

The commonly known iPSCs discovered by Takahashi and Yamanaka (2006) provide a cell source with both the self-renewal capacity and the potential to differentiate into every desired cell type of ecto-, endo-, or mesodermal origin. iPSCs are derived by cellular reprogramming approaches. In general, accessible and abundant differentiated cell types such as fibroblasts are reverted into a pluripotent cell state. The iPSCs are functionally comparable to embryonic stem cells (ESCs) while avoiding the ethical issues related to ESCs (Lo and Parham 2009). However, obtaining iPSCs is not a simple procedure and carries several challenges, such as viral transduction which is based on gene integration, and often results in iPSCs with oncogenic potentials (Tsumaki et al. 2015).

Following iPSC generation, proper differentiation methods are necessary to steer the stem cells into chondrocytes. These methods can be classified in four groups (Fig. 1) and are reviewed by Tsumaki and colleagues (Tsumaki et al. 2015). Although iPSCs seem promising for articular cartilage regeneration, time- and cost-efficiency of the approach are today’s challenges.

Besides iPSC-based reprogramming, direct conversion of fibroblasts into the desired cell type is another approach to obtain a pool of chondrocytes (Ladewig et al. 2013). Direct conversion is based on a similar concept in which cellular reprogramming is central.
Chondrocytes, derived by direct conversion, differ from iPSC-derived chondrocytes in the sense that the acquisition of a PSC fate is not involved. In the field of cartilage regeneration, both techniques have proven to be effective in producing chondrocytes (Diekman et al. 2012; Ko et al. 2014; Hiramatsu et al. 2011). However, the efficiency of the methods and the safety and stability of the derived chondrocytes have not been considered and compared in depth. Additionally, it has not yet been clarified which method is most beneficial for the development of chondrocytes with quality standards adequate for clinical use.

This study aims to define the status quo of cellular reprogramming techniques in cartilage regeneration. The development of chondrocytes by direct conversion or through iPSCs is analysed according to several parameters.

---

**Fig. 1** Chondrogenic differentiation methods applied to iPSCs. 

- **a** Chondrogenic differentiation of iPSCs is driven by co-culture with primary articular chondrocytes in a transwell culture system. 
  - iPSCs are placed into suspension culture to form embryoid bodies (EBs); mesodermal outgrowth is isolated followed by chondrogenic differentiation with pro-chondrogenic growth factors and cytokines. 
- **b** Spontaneous differentiation of iPSCs is carried out in 2D monolayer on gelatin-coated culture plates, MSC-like cells are isolated, and chondrogenic differentiation is stimulated. 
- **d** Directed chondrogenic differentiation is carried out by segmentation of the differentiation protocol; intermediate cell stages are passed towards a chondrogenic phenotype. Adapted from Oldershaw (2012)
criteria that account for the qualification of the methods and the derived chondrocytes. By this study, we hope to provide insights into the reprogramming technique that is most beneficial for clinical cartilage repair.

Articular cartilage: development and physiology

The development of AC takes place during embryonic skeletogenesis. Skeletogenesis begins in the limb bud that is derived from lateral plate mesoderm (Lu et al. 2004). While the lateral plate mesoderm gives rise to the skeleton, connective tissue, and blood vessels, the paraxial mesoderm in the limb develops into muscle precursor cells (Carlson 2013). During early morphological events, pre-cartilaginous condensations appear from the lateral plate mesenchyme in the periphery of the limb bud (DeLise et al. 2000). Following these condensations, a remodelling process is initiated that results in the first sign of joint development marked with flattened cells (Decker 2016). This compact region of flattened cells is defined as the interzone. Interzone-located cells start to express growth and differentiation factor 5 (GDF5) that is mainly responsible for the early development of the joint. Dependent on the following signalling events (i.e. Erg and transforming growth factor-β (TGF-β)), the so-called joint progenitor cells develop into chondrogenic cells that form the articular cartilage (Koyama et al. 2008). While condensations in the periphery of the limb bud give rise to joint-related tissues, the mesenchymal stem cells in central condensations undergo chondrogenic differentiation followed by maturation and proliferation. These cells eventually become hypertrophic chondrocytes that produce type X collagen and matrix metallopeptidase 13 (MMP13) (Bobick et al. 2009). In contrast to articular chondrocytes, hypertrophic chondrocytes maintain a higher proliferation rate and contribute to bone formation via endochondral ossification. Chondrogenesis depends on signalling molecules that act in a temporospatial manner. A schematic representation of the core molecules and chondrogenic signalling events is depicted in Fig. 2. Dependent on the environmental signals that mature articular chondrocytes receive, the cells regulate synthesis of the ECM building blocks: type II, IX and XI collagen, proteoglycans (PGs) and various growth factors and enzymes (Demoor et al. 2014). Type II collagen remains the most abundant isoform that makes up the framework of cartilage (Ergeget and Mandelbaum 2008). A wide range of PGs are embedded in this collagen network and are featured by the unique combinations of glycosaminoglycan (GAG) chains (Gao et al. 2014). Due to the GAG chains, PGs such as aggrecan (ACAN) possess osmotic properties and have the capacity to absorb water which determines the compressive stiffness of the AC (Sophia Fox et al. 2009).

Cellular reprogramming

In the last decade, cell fate reprogramming through forced TF expression has become a trending research area. Due to the rapid developments, the term ‘reprogramming’ is nowadays used in a broader sense, namely the conversion of cell fate. We therefore distinguish the two approaches as follows: induction of pluripotency is defined as reprogramming into pluripotency, whereas direct reprogramming is associated with experimentally changing differentiated cell fates bypassing a state of pluripotency.

Reprogramming into pluripotency

iPSCs were discovered by application of the ‘leave one out’ strategy, also recognized as a top-down approach. The resulting Yamanaka factors essential for pluripotency induction, also known as OSKM—POU class 5 homeobox 1 (Pou5f1 or Oct4), sex determining region Y box 2 (Sox2), Krüppel-like factor 4 (Klf4) and myelocytomatosis oncogene (c-Myc)—were defined from a pool of 24 candidate genes and retrovirally transfected in dermal fibroblasts (DFs). Hereafter, Fbx15-selected iPSCs1 were analysed and the authors concluded that the cells were comparable to ESCs in morphology, cell surface markers, gene expression profile and epigenetic state of pluripotency genes (Takahashi et al. 2007; Takahashi and Yamanaka 2006). Nowadays, it is well-accepted that the core TFs—Oct4, Sox2 and Nanog homeobox (Nanog)—are the masters behind pluripotency, pushing the terminal-differentiated cell back up the hill of Waddington’s epigenetic landscape (Waddington 1942; Ladewig et al. 2013; Niwa 2007). Despite the effectiveness of the TF-based approach, many studies observed a low reprogramming efficiency (<4%) (reviewed by Rao and Malik 2012).

1 Reprogrammed cells are selected with a neomycin resistance gene and β-galactosidase reporter incorporated into F-box protein 15 (Fbx15), a target gene for Oct3/4 that is dispensable for pluripotency.
According to the stochastic model of Yamanaka (2009), only a fraction of the initial cell population achieves ground-state pluripotency explaining the low efficiency. The model elucidates that the yield of a uniform reprogrammed cell population depends on (1) the TF combination, stoichiometry and concentration and (2) exogenous TF silencing after endogenous TF expression is activated, which in turn depends on (3) the epigenetic signature remarkable for PSCs. Epigenetics plays an important role in cellular reprogramming. In somatic cells, pluripotency genes are repressed by DNA methylation and inhibiting histone markers while fibroblast-specific genes are active. Exposure of these somatic cells to exogenous factors induces changes in epigenetic markers that influence (1) repression of genes associated with the host-specific cell lineage and (2)
accessibility of pluripotency genes. However, during this process, epigenetic abnormalities can occur and promote the cells to roll back into their valley due to remaining epigenetic memory of the host cell (Verma and Verma 2011; Sullivan et al. 2010; Kim et al. 2010). Hence, the residual epigenetic signature affects the differentiation potential. Consequently, these iPSCs carry some risks for therapeutic purposes.

Direct reprogramming

Nowadays, it is well accepted that terminal differentiated cells show a degree of plasticity and are convertible to another cell lineage. Direct reprogramming is comparable with naturally occurring transdifferentiation; however, the dedifferentiation stage is generally not observed in experimental direct reprogramming (Jopling et al. 2011). One of the first cases of direct reprogramming was already demonstrated 20 years ago when Weintraub and colleagues converted fibroblasts into myoblasts by transfection of myogenic differentiation 1 (MyoD1) cDNA (Davis et al. 1987). Progress has been made in this field ever since (Akinci et al. 2012; Batta et al. 2014; Ieda et al. 2010; Vierbuchen et al. 2010; Weintraub et al. 1989), and in many of these studies, the key reprogramming factors were developmental regulators of the target cell lineage. Although direct reprogramming holds great promise for regenerative medicine, the mechanism of action is cell type-specific and still largely unknown for many cell types. It is suggested that cells are converted through down-regulation of the original cell-specific genes, while simultaneously activating target cell-specific genes (Sancho-Martinez et al. 2012). Another model proposes the involvement of a dedifferentiation step before the cells are redifferentiated into another cell type. However, many scientists failed to observe the latter mechanism.

Similar to reprogramming into pluripotency, low efficiency affects the direct reprogramming approach. Yet again, this is due to the epigenome of the original cell that impedes appropriate reprogramming by exogenous TFs (Chin 2014; Sancho-Martinez et al. 2012).

Reprogramming into chondrocytes

Research into cartilage regeneration by iPSCs or direct conversion is still in early phase. Since ESCs were the first pluripotent stem cells closely examined for chondrogenic capabilities, these differentiation strategies (Nakagawa et al. 2010; Oldershaw 2012; Han et al. 2010) have also been applied to iPSCs. Many studies aim to optimize the approach by mimicking in vivo chondrogenesis. However, it has not yet been proven that ESCs and iPSCs share the same mechanism of action during chondrogenic differentiation. Furthermore, it is recommended to perform in vitro chondrogenic differentiation through 3D cell culture models in order to prevent dedifferentiation or hypertrophy of the induced chondrocytes.

In contrast to iPSC-mediated chondrocyte generation, direct conversion of fibroblasts into chondrocytes has not been extensively explored (Hiramatsu et al. 2011; Outani et al. 2013). Most likely, this process also takes place in a 3D environment to prevent dedifferentiation. Moreover, it remains important to generate functional and stable chondrocytes with TF-based reprogramming techniques to, in the future, implement these approaches in clinical practice. In order to accomplish this milestone in cartilage regeneration, the chondrocytes need to mimic native articular chondrocytes as closely as possible.

The quality of the reprogramming method for clinical application depends on two factors: (1) the time frame wherein the starting cells are converted into the desired cell type and (2) the efficiency of this conversion. In general, the time frame is determined by the TF combination and the culture conditions. The reprogramming efficiency functions as an exact measurement. In order to assess the overall efficiency, two parameters have to be evaluated: (i) the yield, defined as the percentage of converted cells relative to the number of starting cells, and (ii) the purity, which accounts for the percentage of functional converted cells in the final cell population. Preferably, the costs are also taken into account to assess the cost-effectiveness and cost-efficiency of the method. However, precise cost measurements are difficult and, therefore, only the reprogramming efficiency and the time frame are included to examine the quality of the reprogramming method.

The quality of the generated chondrocytes depends on several criteria that underline the safety and functionality of the cells. Firstly, the cell identity is important to assess to what extent the converted cells adopted a phenotype and genotype similar to their native counterparts. Since articular chondrocytes do not possess a cell surface marker, the chondrogenic identity is confirmed when the following markers are expressed and produced: type II collagen, ACAN, GAG and SOX9. Additionally, a polygonal morphology characterizes the chondrogenic phenotype. Secondly, since clinical
application is the purpose, the safety of the converted cells has to be validated on the basis of (1) genomic stability and (2) epigenetic assembly. Both parameters are closely associated with the tumourigenic features of the converted cells. Karyotyping, whole genome and epigenome sequencing and teratoma analysis are the most common assays to study safety. Preferably, transgenes are silenced or even absent in the final cell population meaning that screening of pluripotency factors (e.g. Oct4, Sox, Nanog) is also required.

The most relevant criterion for cartilage regeneration is the functionality of the derived chondrocyte-like cells both in vitro and in vivo. Evidently, the converted cells have to acquire the capacity to produce and distribute cartilage-specific ECM, eventually leading to the formation of hyaline cartilaginous tissue. However, there is a risk of hypertrophic activity that affects the cartilage-like tissue and results in endochondral ossification. Furthermore, residual epigenetic memory of the starting cell population might affect cartilage-specific ECM architecture by the production of fibroblastic type I collagen. For these reasons, both hypertrophic (i.e. type X collagen, MMP13) and fibroblastic markers have to be assessed in order to gain insights into the cells’ functionality. Cell survival, integration in native tissue and susceptibility to physiological stimuli also define the functionality of the cells.

The iPSC-based detour

From fibroblast to pluripotency

Numerous advanced TF delivery methods to induce pluripotency have been introduced. The method is particularly relevant since it influences the reprogramming efficiency and quality of the iPSC population (Alateeq et al. 2015). Although no consensus has been reached regarding the definition of iPSC quality, they are characterized by their ability to act similar to ESCs. From a genetic perspective, this means that the cells’ genome does not show alterations dissimilar from the starting cell pool (safety). Thus, the absence of transgenes and DNA damage needs to be guaranteed to prevent tumourigenic characteristics. When cells adhere to these aspects, they are labelled with a ‘high-quality mark’. How these features are examined varies in the academic literature.

Subsequently, it is widely acknowledged that non-integrative transduction methods are preferred since these initiate footprint-free iPSCs. Belonging to this group are integration-free viral vectors such as adeno- and Sendai viral viruses (Fusaki et al. 2009; Zhou and Freed 2009), episomal plasmids (Okita et al. 2011), mini-circles (Jia et al. 2010), messenger RNA (mRNA) transfection (Luni et al. 2016) and protein delivery systems (Kim et al. 2009). A state-of-the-art reprogramming method involves microfluidic environments with daily managed delivery of modified mRNA (mRNA) (Luni et al. 2016). Noteworthy is that all methods differ in efficiency, quality, costs and labour intensity. Nevertheless, advancements in cell culture technologies and reprogramming methods provide opportunities for clinical translation. A final consideration regarding the method of interest is the intellectual property landscape that may affect actual implementation.

While integrative delivery systems result in high efficiencies with low iPSC quality, non-integrative reprogramming methods are characterized with remarkably low efficiencies and clinical-grade iPSC generation. Improvement of reprogramming efficiency depends on the identity, interplay and concentration of exogenous TFs, which are in turn related to the starting cell’s genome. In this paper, fibroblasts found the basis for iPSC reprogramming.

Transcription factor identity, combination and concentration

Reprogramming fibroblasts into iPSCs is mainly accomplished by transfection with the original OSKM factors. Since c-Myc is an oncogene, many scientists aim to replace or eliminate this TF in order to prevent tumourigenic characteristics (Han et al. 2010; Chen et al. 2011; Li et al. 2011a; Maekawa et al. 2011). C-Myc has been replaced by factors such as L-Myc, transforming growth factor-β (TGF-β) inhibitors and ascorbic acid/Vitamin C (VitC) and have shown decreased tumourigenesis and enhanced efficiency (Han et al. 2010; Chen et al. 2011; Li et al. 2011a; Maekawa et al. 2011). During reprogramming, a transition to an epithelial cell state is required and accelerates the reprogramming process. This mesenchymal-to-epithelial transition (MET) of fibroblasts is prevented by TGF-β-activity (Li et al. 2010). Normally, c-Myc is enough to suppress both TGF-β1 and TGF-βR2. By replacing c-Myc with TGF-β inhibitors, the oncogene’s
function is taken over by a likely clinical more appro-
appropriate alternative. Others have proven that c-Myc is
dispensable, although the process resulted in a lower
induction of pluripotency that led to latency (Nakagawa
et al. 2010; Wernig et al. 2008).

In addition to factor identity and combination, the
concentration influences reprogramming efficiency since
TFs can interact with chromatin- and histone-modifying
proteins to remove barriers (Cota et al. 2013; Hanna et al.
2009; Yamanaka 2009). It is considered that a higher
amount of TFs accelerates the actions of the remodelling
proteins and enhances reprogramming efficiency.

Small molecules and chemical compounds

Besides TFs, other reprogramming factors such as small
molecules and chemical compounds are widely exam-
ined to replace TFs or boost the reprogramming ap-
proach (Nie et al. 2012; Bar-Nur et al. 2014). These
molecules act in different manners yet are all focussed
on lowering the epigenetic or signalling barriers that
hamper proper and efficient reprogramming (Fig. 3).
In other words, the small molecules are able to modulate
endogenous protein levels and cellular signalling events
that enhance iPSC generation. Examples include a fa-
cilitated MET, a metabolic switch to glycolysis and
epigenetic modification of DNA and histones to a more
‘open’ state (Su et al. 2013). To highlight the latter, PSCs
are characterized with highly acetylated genes
(open/active), while somatic cells are marked with high-
ly methylated genes (closed/inactive). Hence, inhibition
of enzymes responsible for methylation of DNA and
histones (i.e. histone deacetylase and DNA methyltrans-
ferase) (Greer and Shi 2012) steers the cells towards an
open genome which benefits the transition to PSC.

Valproic acid (VPA) is a common histone deacetylase
(HDAC) inhibitor that has proven to accelerate
reprogramming in combination with exogenous OCT4
and SOX2 expression (Huangfu et al. 2008). One-
month treatment of DFs with 0.5–1 mM VPA already
yielded a 1000-fold increase in efficiency and cell col-
lonies that resembled the gene expression profiles of
ESCs. The underlying mechanism of VPA has not yet
been clarified. Since VPA-regulated HDAC inhibition is
non-specific, it is likely that the molecule stimulates
euchromatin structure in general.

VitC was initially introduced as an antioxidant in order
to reduce reactive oxygen species (ROS) caused by OSK
minus c-Myc reprogramming (Esteban et al. 2010).

Down-regulation of ROS prevents cell senescence, and
cells thus become more amendable to reprogramming.
Noteworthy is the combination of VitC and VPA that
further enhances the reprogramming efficiency, suggesting
a synergistic effect. Lastly, research has shown VitC-
dependent epigenetic modifying effects in mouse fibro-
blasts through Jhdm1a/1b activity, confirming that epige-
nome remodelling accelerates the reprogramming process
(Esteban et al. 2010; Wang et al. 2011).

Finally, CHIR99021 has the potential to initiate ex-
pression of pluripotency genes by inhibition of glycogen
synthase kinase 3 (GSK3) that in turn allows β-catenin
to move into the nucleus where this transcription factor
initiates expression of OCT4 and NANOG (Han and
Yoon 2011). Notably, in combination with VPA and
minimally required TFs (i.e. only Oct4), reprogramming
efficiency is improved to 0.3%, thus making Sox2 and
Klf4 dispensable (Li et al. 2011b).

Above elaborated small molecules have proven to be
powerful alternatives or supplements for the
reprogramming factor by lowering major epigenetic
and signalling barriers. Nevertheless, there are limita-
tions to small molecule-only reprogramming ap-
proaches such as non-specific activity and increased
costs due to continuous treatment.

From pluripotency to chondrocyte

Traditionally, chondrogenic differentiation is carried out
through spontaneous embryoid body (EB) formation by
iPSCs (Fig. 4a) (Teramura et al. 2010). However, we
concentrate on multistep-directed differentiation
methods since this type of approaches matches in vivo
chondrogenic differentiation of PSCs more closely and
is often described in academic literature.

The most simple directed culture method involves
initiation of MSC-like cells followed by growth factor-
induced chondrocyte differentiation. Guzzo et al. (2013)
demonstrated the development of MSC-like cells after
undifferentiated human induced pluripotent stem cells
(hiPSCs) were directly seeded on gelatin-coated plates
and stimulated by MSC induction media (Fig. 4b). The
derived hiPSC-MSC-like cells showed substantial ma-
trix production and expressed SOX9, COL2A1 and
ACAN, while collagen type I alpha 1 (COL1A1) and
COLXA1 remained minimally expressed. Interestingly,
the iPSC-MSC-like cells showed a higher chondrogenic
potential compared to bone marrow-derived MSCs; ex-
pression of the SOX trio was significantly higher,
whereas runt-related transcription factor 2 (RUNX2) and COL1A1 expression was low in iPSC-MSC-like cells. These data indicate that iPSC-derived MSCs offer advantages over BM-MSCs (Guzzo et al. 2013). Nejadnik et al. (2015), who followed a comparable protocol, observed a conversion of 90% of the hiPSCs to hiPSC-MSC phenotype, which is highly efficient compared to EB-regulated MSC generation. The hiPSC-MSC-chondrocytes established by pellet culture and encapsulation in PEG/CS hydrogels expressed cartilage markers. Meanwhile, immunostaining revealed the presence of COL10A1 that ideally should be low.

There are multiple studies that use standard MSC induction medium and culture for approximately 2–3 weeks before a uniform MSC population is visible (Hynes et al. 2013; Kang et al. 2015). A way to improve this process is given by Chen et al. (2012) who stimulated chronologically MET and epithelial-to-mesenchymal transition (EMT) by addition of small molecules (i.e. TGF-β pathway inhibitor SB431542) (Fig. 4c). Consequently, the cells adapt an epithelial phenotype and MSC markers are barely expressed. However, when the cells are transferred to MSC induction medium, up-regulation of MSC cell surface markers could already be detected after one to two passages. Furthermore, the iPSC-MSC-like cells possessed trilineage differentiation capacity, had a normal karyotype and did not form teratomas, thereby being clinically safe and functional. Umeda et al. (2012) further specified the method by administration of a GSK3 inhibitor, Noggin and SB431542 (Fig. 4d). Subsequently, chondrogenic paraxial mesoderm appeared from iPSCs that underwent sequential chondrogenic differentiation using platelet-derived growth factor (PDGF), TGF-β3 and bone morphogenetic protein (BMP)-4. This approach further fragmented chondrogenesis, which gave rise to more hyaline-like cartilaginous particles compared to MSC-derived cartilage-like constructs. Remarkably, activin A could induce
a Classical differentiation method (Teramura 2010)

iPS cells | MSC-like cell | Cartilage-like tissue
---|---|---
Spontaneous EB formation | Isolation of MSC outgrowth | MSC proliferation till P4 (+ FGF-2) | Chondrogenic differentiation in pellet culture (+ BMP-2, TGF-β) | 21' 

b Guzzo et al. (2012) / Nejadnik (2015)

iPS cells | MSC-like cell | Cartilage-like tissue
---|---|---
MSC induction (+ FGF-2) | MSC proliferation till P3 (+ 10% FBS, FGF-2) | MSC isolation by FCM | Chondrogenic differentiation in micromass culture (+ TGF-β1, BMP-2, AA2P) | 21' 

c Chen et al. (2012)

iPS cells | Epithelial-like cell | MSC-like cell | Cartilage-like tissue
---|---|---|---
MET induction by SB431542 | EMT/MSC induction till P2 (+ 10% FBS) | MSC isolation by FCM | Chondrogenic differentiation in pellet culture | 28' 

d Umeda et al. (2012)

iPS cells | Paraxial mesodermal-like cell | Cartilage-like tissue
---|---|---
MSC induction by SB431542, AGi, Noggin | Paraxial mesoderm isolation by FCM | PDGF | TGF-β3 | BMP-4 | Chondrogenic differentiation in micromass culture | BMP-4 | 10' | 16' 

e Lee et al. (2015)

iPS cells | Chondrocyte-like cell | Cartilage-like tissue
---|---|---
Chondrogenic EB formation by WNT3A, activin A, BMP-4, ROCK inhibitor | Chondrogenic induction (+ FGF-2, BMP-4, FS, NT-4, GDF-5) | SOX9+ cell isolation by FCM | Chondrogenic differentiation in pellet culture (+ IGF, FGF2) | 28' 

f Yamashita et al. (2015)

iPS cells | Cartilage-like tissue
---|---
Mesendodermal induction by WNT3A, activin A | Chondrogenic induction in adhesion culture (+ VitC, BMP-2, TGF-β1, GDF-5) | Cellular particle transfer to suspension culture | Chondrogenic differentiation of particles (+ VitC, BMP-2, TGF-β1, GDF-5) | 28'
paraxial mesoderm from ESCs, whereas it does not have this capacity in iPSCs. This indicates that iPSC and ESCs differ in growth factor susceptibility and adopt distinct differentiation pathways.

Beside the three-stage chondrocyte differentiation methods, many reviews and articles cite the multistage protocol from Oldershaw et al. (2010), which sequentially exposed the cells to different growth factors in combination with substrates of matrix proteins. The protocol, which exploits feeder-free and serum-free culture media, produced ESC-derived chondrocyte-like cells with high expression of Col2A1 and Sox9 and sulphated GAG deposition. Significant growth factors include wingless-type family member 3a (WNT3A), activin A, follistatin (FS), BMP-4, FGF-2 and growth and differentiation factor 5 (GDF-5). While the protocol was designed for PSCs, multiple experiments on iPSCs were unsuccessful wherein decline in iPSC viability was the main limitation. Optimization of the stage-gating method was focussed on the modulation of Wnt- and TGF-β-signalling that could improve the generation of chondrogenic mesoderm (Umeda et al. 2012). Lee et al. (2015) introduced the short-term differentiation of hiPSCs in EBs with chondrogenic mesodermal preferences (Fig. 4c). Along with this, the p160-ROCK inhibitor Y27632 was added to prevent dissociation-induced iPSC apoptosis. Beside this function, ROCK inhibition is associated with increased GAG synthesis and elevated SOX9 expression in differentiated chondrocytes (Woods et al. 2005), making this small molecule also beneficial for chondrogenic differentiation. This protocol yielded 98% SOX9+ cells. Pellet cultures resulted in expression levels of the SOX trio as well as COL2A1 and ACAN comparable to primary adult chondrocytes. Interestingly, cell proliferation was enhanced and induced chondrocytes continued to express SOX9 after 14 passages. This proliferation capacity is remarkable for chondrocytes and could be beneficial for therapeutic applications. Finally, safety and functionality were assured by the absence of subcutaneous teratoma formation and the presence of cartilage-like tissue similar to the control adult chondrocyte-laden hydrogels. The authors suggest that the factors involved in the RhoA/ROCK-, Wnt- and activin A signalling pathways led to increased chondrogenic differentiation of the hiPSCs.

While most studies require a 3D cell culture assay to effectively engineer cartilage construct, Yamashita et al. (2015) recently introduced a strategy to generate scaffoldless hyaline cartilaginous tissue construct from hiPSCs (Fig. 4f). Briefly, hiPSCs-MSCs were exposed to VitC, BMP-2, TGF-β1 and GDF-5 (abbreviated as ABTG). Remarkably, at day 42 the chondrogenic particles showed increased type I collagen staining and maintained this expression up to day 140. The replacement of chondrogenic medium at day 42 with conventional medium resulted in increased GAG staining, while type I collagen expression was decreased. These results suggest that ABTG is only necessary for a specific culture period, in which hiPSCs are committed to the chondrogenic lineage, but it is not continuously required. Uniquely, this protocol exhibits purification steps without the use of cell sorting techniques. The researchers namely suggest that non-mesendodermal cells undergo apoptosis due to the low foetal bovine serum (FBS) concentrations. Furthermore, transfer of non-adhesive nodules to a suspension culture contributed to the removal of non-chondrogenic cells, thus resulting in a pure chondrogenic cell population.

In conclusion, it is of great importance to apply the most optimal set and spatiotemporal pattern of growth factors to steer the iPSCs chronologically towards the chondrogenic cell lineage. According to the available studies, the main growth factors applied to induce iPSC towards MSC-like cells are WNT3A, activin A and FGF-2 or small molecules that interfere with the Wnt- and TGF-β-pathways. Further differentiation of (chondrogenic-committed) MSC-like cells is established by exposure to common chondroinductive growth factors, such as TGF-β homologues, BMP-2/4 and GDF-5. These molecules are consistent with the compounds identified by Yang et al. (2012) that were shown to promote chondrogenesis in iPSCs. Secondly, inclusion of cell selection and isolation techniques is necessary to increase the yield and safety of the resulting chondrogenic cell population. Unfortunately, chondrocyte-specific surface markers have not been identified to date, precluding flow cytometry (FCM). However, the selection of chondrocyte-like cells can

Fig. 4 Schematic representation of the chondrogenic culture protocols described in chapter 3.2. AA2P ascorbic acid 2-phosphate, Agi glycogen synthase kinase-3 (GSK3) inhibitor, BMP-2 bone morphogenetic protein 2, BMP-4 bone morphogenetic protein 4, FBs foetal bovine serum, FCM flow cytometry, FGF fibroblast growth factor, GDF-5 growth and differentiation factor 5, IGF insulin growth factor, NT-4 neurotrophin 4, PDGF platelet-derived growth factor, SB431542 TGF-β inhibitor, TGF-β transforming growth factor-β, VitC vitamin C/ascorbic acid, WNT3A wingless type family member 3a

βVitC, BMP-2, TGF-β1 and GDF-5 (abbreviated as ABTG).
be accomplished with cartilage-specific gene-GFP constructs such as Col11A2-EGFP reporter genes (Diekman et al. 2012).

**Direct reprogramming into chondrocytes**

**Intra-mesodermal reprogramming**

Within the mesoderm, studies have shown the ability to directly convert fibroblasts into functional myocytes (Weintraub et al. 1989), cardiac muscle cells (Efe et al. 2011; Ieda et al. 2010), macrophages (Feng et al. 2008) and chondrocytes (Hiramatsu et al. 2011). Many reports discuss the concept that cells with shared epigenetic landscapes will reprogram more efficiently. This may be explained by the shared cell progeny and the degree of similarity between epigenetic marks and profile. Basically, this mutual epigenetic profile indicates that less epigenetic barriers have to be crossed (Sebban and Buganim 2016; Bernstein et al. 2007). Indeed, in Waddington’s epigenetic landscape, cell lineages within a germ layer are separated by lower ‘hills’ compared to the hills between different germ layer-originating cell types (Ladewig et al. 2013). However, direct lineage reprogramming and thus avoidance of a pluripotent state may result in preservation of host cell-originating epigenetic barriers that might affect the stability of the induced cell fate. As a consequence, the cells ‘roll back’ to the starting cell lineage.

**Mechanism of action**

Similar to iPSCs, fibroblasts are exposed to the top-down approach that eventually results in a core TF cluster for the desired cell lineage. Since this method is cost-consuming, inefficient and unscalable, a predicate computational system (Mogrify) provides an alternative for identification and validation of reprogramming factors (Rackham et al. 2016). Intra-mesodermal reprogramming is mainly demonstrated by administration of lineage-instructive TFs to fibroblasts, in this article referred to as lineage-instructive reprogramming. During this approach, it is assumed that epigenetic barriers cross-over without passing a pluripotent cell fate. Alternatively, an epigenetic activation phase can be introduced (Pournasr et al. 2011) before lineage-specific development clues are applied. This approach involves transient low-level expression of Oct4, Sox2, Klf4 and c-Myc that stimulates a partially pluripotent intermediate stage (Efe et al. 2011). According to this study, efficiency is improved by several folds, suggesting that a more open chromatin state enhances susceptibility to lineage-specific factors and subsequently accelerates the reprogramming process. Indeed, the pluripotency factors induced removal of epigenetic barriers resulting in a dedifferentiation or progenitor intermediate cell state (Ang et al. 2011; Pournasr et al. 2011; Ma et al. 2013b). Following this, lineage-instructive TFs stimulate the differentiation into the desired somatic cell, which is associated with the adoption of a ‘new’ epigenetic regulatory network.

Theoretically, this method provides a short time frame that allows cell expansion due to self-renewal capacities of the cells. For cartilage regeneration, this would be beneficial since clinical implantation requires a high density of chondrocytes. However, full acquisition of a pluripotent state has to be prevented since prolonged induction of the pluripotency network has shown to inhibit cell type conversion (Efe et al. 2011).

**From fibroblast to chondrocyte**

Although DFs are readily accessible and show distinct expansion capacities, the propensity to produce high levels of type I collagen is an obstacle. Residual fibroblastic cell features may affect in vivo regeneration of AC and instead result in fibrocartilaginous tissue. Another concern is the risk of hypertrophic activities of induced chondrocytic cells, which is often observed in chondrogenic differentiation of BM-MSCs (Pelttari et al. 2008). Nevertheless, prior studies have shown the ability of DFs to differentiate into the chondrogenic phenotype and the formation of cartilage-mimicking tissue from these cells, simply by modification of culture conditions (Cui et al. 2004; Junker et al. 2010; Mizuno and Glowacki 1996; Yates et al. 2004).

**TF-mediated reprogramming**

Hiramatsu et al. (2011) were the first who demonstrated chondrocyte generation of fibroblasts by forced TF expression. Continuous retroviral expression of c-Myc, Klf4 and Sox9 (which have shown to be indispensable) yielded colonies with an efficiency of 0.3%. However, after polygonal morphology assessment and GAG staining, the efficiency decreased to 0.08%. Notwithstanding, positive GAG, type II collagen and ACAN were
observed after pellets were cultured with chondrogenic-induced mouse DFs (iChon). On the contrary, hypertrophic gene expression (i.e. type X collagen and Mmp13) was undetectable. Interestingly, the authors included DNA methylation analysis to assess the differences in promoter accessibility. The iChons contained methylated CpGs in the promoters of fibroblast-associated genes Col1a1 and Col1a2, while in the parental MDFs these promoters were unmethylated. This indicates that epigenetic reprogramming took place. Controversially, two out of seven induced cell lines showed significant levels of type I collagen expression. However, these expression levels might be explainable by a pool of incompletely converted fibroblasts. Unfortunately, the iChons appeared to be unsafe since inappropriate karyotyping and subcutaneous tumour formation with abundant type I collagen were observed. With persistent c-Myc expression in mind, the researchers switched to transient TF expression with a DOX-inducible lentivirus. Cultured in chondrogenic induction medium (containing 1% FBS, TGF-β1, GDF-5 and AA2P), the cells maintained high endogenous Sox9 expression. Nevertheless, close examination demonstrated elaborated expression of Col10a1 and Mmp13. This is consistent with the observations of Tam et al. (2014) who compared constitutive (iChon^con) and transient (iChon^ind) chondrogenic-induced MDFs regarding cellular hypertrophy and stability. Upon chondrogenic differentiation, both iChon^ind and iChon^con showed significant expression of type II collagen, while type X collagen was only increased in iChon^ind. Similarly, in vivo analysis associated iChon^ind-regulated tissue formation with bone-like characteristics, whereas iChon^con were able to form stable cartilage containing cells. In addition to the results of Hiramatsu et al., this suggests that prolonged exogenous Sox9 expression is required to obtain chondrogenic cells resistant to hypertrophy. It is surprising that high endogenous Sox9 expression, present in transient-induced iChons, is not able to inhibit these hypertrophic characteristics while Sox9 is known to inhibit osteochondral ossification of native chondrocytes (Hattori et al. 2010; Liao et al. 2014).

A follow-up study performed in human DFs (hDFs) exhibited remarkable differences with mDFs (Outani et al. 2011). The hiChons for example did not produce type I collagen after a sustained period of pellet culture. Additionally, COL10A1 and MMP13 gene expression was undetectable and subcutaneous injection of the cells did not lead to tumour formation, but cartilage-like nodules did. Also, hDFs were more susceptible to the reprogramming approach with a conversion efficiency of 0.24%. In general, the above elaborated reprogramming approach does not involve a pluripotent intermediate state since mRNA expression of PSC markers was not detected (Outani et al. 2011). However, a progenitor intermediate state recognized by dedifferentiation marks cannot be excluded by the evidence presented.

Overall, the choice between constitutive and transient direct lineage reprogramming into chondrocytes remains a topic that has to be further explored. Ideally, transgene integration is avoided in order to prevent teratoma formation, increasing the suitability for clinical application (Sebban and Buganim 2016). Nevertheless, it is acknowledged that continuous expression of the reprogramming factors c-Myc, Klf4 and especially Sox9 is required.

Non-TF-mediated reprogramming

As already mentioned, direct reprogramming into chondrocytes was demonstrated by modified culture conditions, hence without exogenous TF expression. In 1996, Mizuno and Glowacki showed chondrogenic effects of demineralized bone powder on DFs cultured in 3D compositions. Nowadays, several studies identified agents, biomaterials and scaffolds that facilitate direct reprogramming towards chondrocyte-like cells (Bussmann et al. 2013; Kino-Oka et al. 2009; Nam et al. 2014; Yin et al. 2010). Medium containing low FBS concentration (2–5%) and GDF-5 is sufficient to induce chondrogenic characteristics, such as endogenous SOX, ACAN and type II collagen expression, by DFs in micromass culture (Yin et al. 2010). Despite the simple protocol, high type I collagen expression is sustained, assuming that the original epigenetic program is not completely reset and/or non-chondrogenically differentiated DFs are still present. Exposure of hDFs to 5% FBS, TGF-β3 and AA2P embedded in a soft hydrogel (i.e. RAD16-I peptide network) improved chondrogenic differentiation of hDFs (Bussmann et al. 2013). Although enhanced and homogeneous cartilage-specific ECM production was observed, type I collagen remained present during the whole culture period. However, a low level of type I collagen is usually also found in native AC. Interestingly, in vitro passaged chondrocytes and fibroblasts share phenotypic characteristics (Nam et al. 2014; Kino-Oka et al. 2009). Also, dedifferentiation of chondrocytes in monolayer
expansion is correlated with increased expression of fibre-associated collagens (Goessler et al. 2004). Counteraction by redifferentiation approaches in 3D models (Schulze-Tanzil et al. 2002; Das et al. 2013) might correspond to the chondrogenic conversion of fibroblasts and improve the quality of iChons. This way of reasoning indicates that epigenetic similarities between fibroblasts and chondrocytes co-exist.

Another culture modification widely studied in MSC-based chondrogenic differentiation is the introduction of a hypoxic environment. In brief, low oxygen increases the production of hypoxia-inducible factor 1α (HIF-1α) that in turn initiates transcription of genes such as type II collagen, Sox9 and chondroitin sulphate (Kanichai et al. 2008; Robins et al. 2005). Hypoxia and HIF-1α are also acknowledged to simultaneously inhibit expression of COL1A1 and COL1A2 (Duval et al. 2009). Therefore, it is hypothesized that low oxygen concentrations (5% O2) improve chondrogenic conversion of fibroblasts and regulates fibroblastic type I collagen production. Indeed, fibroblasts cultured in hypoxic conditions and chondrogenic medium have shown to lower type I collagen abundance compared to normal culture conditions (20% O2) (Kalpakci et al. 2014; Singh et al. 2011). Although hypoxic differentiation advances the cells further towards a chondrogenic phenotype, the attendance of residual fibroblasts cannot be excluded and therefore represents a risk for human transplantation.

To conclude this chapter, DFs, especially from human origin, are highly susceptible and amendable to direct lineage reprogramming. Groundbreaking studies in this field were presented by Hiramatsu and Outani who demonstrated the expression of cartilage-specific markers. Also, proliferation activities were high and therefore beneficial for cartilage regeneration. Reprogramming efficiencies were rather modest and comparable with the iPSC detour. Limitations to overcome include hypertrophic chondrocyte maturation and the deposition of abundant type I collagen. The latter may be caused by an incomplete epigenetic reset that results in partially converted cells. Hypertrophy can only be prevented by constitutive exogenous TF expression; however, integrative reprogramming methods are unfavourable for clinical translation. Lastly, a pluripotent state was negligible. However, the involvement of a progenitor state is not excluded and might even be valuable. Moreover, epigenetic similarities between the cell types may enable direct reprogramming. Further research into the epigenetic progeny of the two cell lineages may offer valuable insights for the approach to eventually generate long-term functional and stable chondrocytes safely and efficiently.

Discussion

In this paper, two distinct reprogramming approaches are examined as a potential strategy to obtain a new cell source for AC regeneration. From a clinical perspective, the derived chondrocyte population has to be safe, functional and sufficient in size. As demonstrated in the chapters, the quality of the chondrocyte-like cells highly depends on the type of reprogramming method including the combination and concentration of TFs and the manner of exposure (i.e. constitutive or transient exogenous expression). In addition to forced TF expression, both reprogramming methods may be improved by small molecules, chemical compounds and functionalized 3D cell culture systems. An overview of several aspects with regard to the reprogramming strategies and resulting chondrogenic cells is given in Table 1.

Cartilage formation through iPSC generation is a two-stage approach that is acknowledged as a protracted and inefficient method. Nevertheless, the strategy is suitable for the acquisition of a sufficient number of chondrocytes due to enhanced self-renewal of iPSCs. Active cell proliferation is favourable since it ‘opens’ the starting cell’s genome and allows rapid modifications towards pluripotency. Originally, entrance of the cell cycle is initiated by c-Myc. However, the risk for random mutagenesis that reduces the safety of the iPSCs has to be limited for clinical application. Therefore, substitutes such as L-Myc, TGF-β inhibitors and VitC provide alternatives to the oncogenic gene. Noteworthy is that the initiation of MET with TGF-β inhibitors improves the initial stage of reprogramming into pluripotency. For this reason, it is suggested that the generation of iPSCs requires a transition to an epithelial gene expression pattern and that epithelial cells might be more efficient. Indeed, skin keratinocytes have shown a more efficient and rapid iPSC generation compared to human fibroblasts (Aasen et al. 2008). Interestingly, Borestrom et al. (2014) created chondrocyte-derived iPSC with a higher matrix-producing capacity compared to fibroblast-derived iPSCs after chondrogenic differentiation. Thereby, the researchers show that the starting cell type for the iPSC detour towards clinical cartilage
influences the quality of derived chondrocytes. Future studies into cartilage formation through iPSC generation need to consider the type of starting cell and the effect on resulting chondrocytes.

Most researchers performed directed chondrogenic differentiation by temporal and sequential application of defined factors in order to mimic embryonic chondrogenesis. This stage gating provides advantages over other methods in a way that it produces a high cell yield and a homogeneous chondrocyte population. However, cell homogeneity highly depends on the inclusion of appropriate (intermediate) cell selection techniques. The cell yield is difficult to assess since directed differentiation induces high proliferation rates. Thus, the effect of temporal growth factor exposure on differentiation efficiency remains unclear. Interestingly, the iPSC-derived MSC-like cells show higher expansion capacity and reduced chondrocyte maturation in contrast to native adult MSCs. From this point of view, iPSCs provide more profits over MSCs as an adult stem cell source for cartilage regeneration.

Cell yield and homogeneity as well as culture period can be further improved by early initiation of paraxial mesodermal cells. Remarkably, paraxial mesoderm differentiation from iPSCs is characterized by the same molecular factors involved in iPSC generation from fibroblasts, including Wnt3a, activin A, SB431245 and BMP-4. Differential effects of these components might be explainable by the difference in starting cell type (iPSC and fibroblast, respectively). In PSCs, it has indeed been shown that the TGF-β/activin/nodal branch of the TGF-β signalling pathway plays a crucial role in the maintenance of stem cell identity (James et al. 2005). Thus, when TGF-β is inhibited by SB431245, the PSCs enter the early cell fate determination phase while in later stages of differentiation TGF-β activity enhances chondrocyte development (Yang et al. 2009). Thus, exposure of iPSCs to factors such as TGF-β has to be performed in a critical time- and dose-dependent manner to prevent incorrect cell fate determination. Nowadays, many researchers examine in vitro directed chondrogenesis. However, a distinction between ESC-, iPSC- and adult MSC-mediated chondrocyte differentiation has to be kept in mind.

A serious drawback of iPSC-based chondrocyte development is the prolonged culture period (approximately 2–3 months) and the high costs of all the transcription and growth factors, extracellular matrix molecules and 3D niches necessary for efficient iPSC generation and especially directed chondrogenic differentiation. Time and costs may be diminished by the use of allogeneic clinical-grade iPSc cell lines that match the patient’s human leukocyte antigen (HLA) type (Turner et al. 2013). Indeed, efforts are initiated in iPSC banking to offer high-quality allogeneic iPSCs cultured under GMP conditions (Taylor and Jones 1979; Turner et al. 2013). These donor banks may facilitate regulatory approval due to extensive donor screening and testing compared to autologous iPSC.

### Table 1 An overview of the two reprogramming methods and the quality of the derived chondrocytes

|                  | iPSC-based ‘detour’ | Direct lineage reprogramming |
|------------------|---------------------|-------------------------------|
| **Fibroblast to iPSC** | 89–97% | **Time frame** | Weeks–months | Hours–days |
| **iPSC to chondrocytes** | <0.24% | **c-Myc requirement** | No | Yes |
| **Efficiency** | <4% | **Transgene dependency** | N.A. | Yes |
| **Time frame** | 3–8 weeks | **Transgene silencing required** | Yes | No |
| **Expandable** | Yes | **Risk for tumourigenesis** | Yes, low | High/low |
| **Fibroblast markers** | Yes, very low | **Fibroblast to chondrocyte** | N.A. | Yes, moderate |
| **Hypertrophic activity** | Low | **Risk for tumourigenesis** | N.A. | Low/High |

N.A. not applicable, N.I. not included

a c-Myc can be replaced by L-Myc, TGF-β inhibitors and vitamin C

b As long as isolation and purification of the intermediate cell population are included
c Constitutive
d Transient

---

Cell Biol Toxicol (2017) 33:329–349
generation. Also, the implantation of allogeneic cells into cartilage defects may be allowed more easily since AC is immuno-privileged due to its avascular nature.

In contrast to the iPSC detour, intra-mesodermal direct lineage reprogramming may require less epigenetic barriers to be crossed due to a mutual epigenetic landscape. Therefore, a lower epigenome remodelling rate is needed and this may reduce the risk of random mutagenesis and hence teratoma formation. Indeed, fibroblast-derived chondrocytes did not develop tumours in immunodeficient mice which may be explained by the shortened culture period with c-Myc. Opposite to teratoma formation, it is serious to consider the risk for fibrocartilaginous cartilage. Since chondrocytes cannot be isolated from fibroblasts on the basis of cell surface markers, there remains a high risk on the presence of non- or partially converted fibroblasts that in vivo contribute to the formation of non-functional fibrocartilaginous cartilage.

A serious issue of existing direct conversion techniques is the requirement of constitutive transgene expression. In particular, exogenous Sox9 seems to be indispensable to generate stable cartilaginous tissue and prevent hypertrophy. Meanwhile, high endogenous levels of Sox9 were not able to suppress hypertrophic maturation, suggesting that the activity of endogenous Sox9 was impaired. Posttranslational modifications of Sox9 via PKA-mediated phosphorylation determine the activity of Sox9 and to what extent the protein inhibits hypertrophy (Akiyama 2008). Also, the parathyroid hormone-related protein (PTHrP) receptor is mainly responsible for Sox9 phosphorylation (de Crombrugghe et al. 2000). It might be possible that this cartilage-specific receptor is not yet activated and alters Sox9 activity. On the other hand, it has been suggested that the epigenetic status of the cell influences the Sox9-regulated transcriptional network for chondrocyte differentiation (Furumatsu and Asahara 2010). According to Leung et al. (2011), Sox9 inhibits Col10a1 transcription by binding to the gene’s regulatory elements. Thus, it is argued that this regulatory domain is not yet accessible for Sox9 in chondrogenic-induced fibroblasts. Finally, Takahashi (2012) proposed that the endogenous gene products act in synergy with the exogenous factors to enable activation of the full chondrogenic transcriptional network. Hiramatsu and colleagues stimulated the cells for only 2 days, which suggests that prolonged exogenous transduction is mandatory to completely activate the chondrogenic transcription circuit in fibroblasts. In addition to this, the researchers cultured the induced cells in monolayer, though it is commonly known that articular chondrocytes require a 3D environment to preserve their polygonal morphology and to deposit their synthesized ECM components. Advanced biomaterials composed of cartilage-specific ECM components to induce particular cell responses (Elisseeff et al. 2006) together with extended exogenous Sox9 exposure may improve the chondrocytes’ stability and prevent hypertrophy. The application of biofunctionalized materials may also provide a solution to the long culture period of iPSC-based chondrocyte differentiation.

Although native articular chondrocytes express a basal type I collagen concentration, transiently induced fibroblasts continued to synthesize high levels of type I collagen. Consequently, the cartilage-like tissue constructs resemble rather fibrocartilaginous than AC tissue. The occurrence of type I collagen can be explained by (1) the presence of non- or partly converted fibroblasts or (2) the reconversion of the cells back to the fibroblast lineage. In both cases, it is assumed that epigenetic remodelling was not sufficient to erase and block fibroblast-specific gene expression. A potential solution is the inclusion of an epigenetic activation phase that may lead to epigenetic erasure of fibroblastic differentiation marks before the cells are exposed to chondrogenic development clues. This strategy minimizes epigenetic memory, and it makes the cells more susceptible to reprogramming factors. More importantly, it allows the cells to expand during the intermediate phase, which is not possible in lineage-instructive reprogramming.

A last generic discussion point regarding both approaches is the lack of proper controls and epigenetic screening in the reviewed studies. Obviously, both iPSC-derived and fibroblast-derived chondrogenic cells have to be safe and functional, meaning that genetic aberrations must be minimized and functional epigenetic characteristics of the starting cell type (i.e. fibroblasts) have to be absent. Currently, these features are barely studied before and after initiation of in vitro chondrogenic differentiation. Additionally, the derived chondrogenic cells are compared to native articular chondrocytes only in a few studies. Future research should include examination, by for example genome and epigenome sequencing, to assess the quality of the derived chondrocytes for clinical application.

**Conclusion**

Nowadays, reprogramming strategies are of high interest in clinical research to develop a new cell source for
regenerative medicine and tissue engineering. Both approaches elaborated in this article allow the use of abundant, accessible and autologous somatic cells for cartilage formation, yet are still inefficient and time- and cost-consuming. Direct lineage reprogramming provides a slight advantage over these aspects compared to the iPSC detour. However, the risk of fibrocartilaginous tissue due to residual fibroblastic cells is a serious consideration for bringing this approach to the clinic.

In our opinion, the iPSC detour for cartilage regeneration is currently closer in the vicinity of the clinic due to more progress and attention in the safety- and efficacy-related aspects of the method and derived cells. For instance, the risk of teratoma formation has been minimized by improvement of the approach in the absence of oncogenes, contrary to direct lineage reprogramming that still requires constitutive transgene expression. Also, expansion of the cell number, needed for in vivo cartilage regeneration, is easier in the presence of a pluripotent cell state during the reprogramming process. Lastly, directed differentiation of iPSCs allows the application of cell isolation techniques to derive a homogenous cell population that in turn contributes to the safety and functionality of the cells. Overall, more academic attention is needed for direct lineage reprogramming in order to compete with the iPSC detour for clinical purposes in the field of cartilage repair.

Finally, many scientists acknowledge the importance of epigenetic memory in chondrocyte safety and functionality. For this reason, it remains significant to include epigenetic profiling of reprogrammed cells and compare this to appropriate control groups. The future challenge is to tackle current drawbacks by further research into the optimal reprogramming and culture conditions while holding the clinical objectives in mind. This includes studies focussed on the identification and determination of small molecules, chemical components and (hypoxic) 3D microenvironments that promote chondrogenic reprogramming and prevent tumourigenic, fibroblastic and hypertrophic activities.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008;26:1276–84.

Akinci E, Banga A, Greder LV, Dutton JR, Slack JM. Reprogramming of pancreatic exocrine cells towards a beta (beta) cell character using Pdx1, Ngn3 and MafA. Biochem J. 2012;442:539–50.

Akiyama H. Control of chondrogenesis by the transcription factor Sox9. Mod Rheumatol. 2008;18:213–9.

Alateeq S, Fortuna PR, Wolvetang E. Advances in reprogramming to pluripotency. Curr Stem Cell Res Ther. 2015;10:193–207.

Ang YS, Gaspar-Maia A, Lemischka IR, Bernstein E. Stem cells and reprogramming: breaking the epigenetic barrier? Trends Pharmacol Sci. 2011;32:394–401.

Bar-Nur O, Brumbaugh J, Verheul C, Apostolou E, Pruteanu-Malinici I, Walsh RM, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Meth. 2014;11:1170–6.

Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, Melen GJ, Sanchez L, Ligero G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol. 2008;28:6609–19.

Batta K, Florkowska M, Kouskoff V, Lacaud G. Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells. Cell Rep. 2014;9:1871–84.

Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, et al. SOX9 directly regulates the type-II collagen gene. Nat Genet. 1997;16:174–8.

Bernstein BE, Meissner A, Lande RS. The mammalian epige- nine. Cell. 2007;128:669–81.

Bobick BE, Chen FH, Le AM, Tuan RS. Regulation of the chondrogenic phenotype in culture. Birth Defects Res Part C, Embryo Today Rev. 2009;87:351–71.

Borestrom C, Simonsson S, Enochson L, Bigdeli N, Brantsing C, Brittberg M, et al. Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: a first step toward a clinical-grade cell source. Stem Cells Transl Med. 2014;3:433–47.

Brietburg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994;331:889–95.

Bussmann BM, Reiche S, Mari-Buye N, Castells-Sala C, Meisel HJ, Semino CE. Chondrogenic potential of human dermal fibroblasts in a contractile, soft, self-assembling, peptide hydrogel. J Tissue Eng Regen Med. 2013;10:154;E54–62.

Carlson BM. Human embryology and developmental biology: Elsevier Health Sciences; 2013.

Caron MM, Emans PJ, Cremers A, Surtel DA, Cooslen MM, van Rhijn LW, et al. Hypertrophic differentiation during chondrogenic differentiation of progenitor cells is stimulated by BMP-2 but suppressed by BMP-7. Osteoarthr Cartil. 2013;21:604–13.

Chen J, Liu J, Yang J, Chen Y, Chen J, Ni S, et al. BMPs functionally replace Klf4 and support efficient
reprogramming of mouse fibroblasts by Oct4 alone. Cell Res. 2011;21:205–12.

Chen YS, Pelekanos RA, Ellis RL, Horne R, Wolvetang EI, Fisk NM. Small molecule mesengetic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med. 2012;1:83–95.

Chin MT. Reprogramming cell fate: a changing story. Front Cell Dev Biol. 2014;2:46.

Cota P, Shafa M, Rancourt DE. Stem cells and epigenetic reprogramming 2013–2018.

Cui L, Yin S, Deng CL, Yang GH, Chen FG, Liu W, et al. Cartilage-derived morphogenetic protein 1 initiates chondrogenic differentiation of human dermal fibroblasts in vitro. Zhonghua Yi Xue Za Zhi. 2004;84:1304–9.

Das S, Pati F, Chameettachal S, Pahwa S, Ray AR, Dhara S, et al. Enhanced redifferentiation of chondrocytes on microperforated silk/gelatin scaffolds: toward tailor-made tissue engineering. Biomacromolecules. 2013;14:311–21.

Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987;51:987–1000.

de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami M, Fabre H, et al. Cartilage tissue engineering: molecular control of chondrocyte differentiation for proper cartilage matrix reconstruction. Biochim Biophys Acta. 2014;1840:2414–40.

Diekman BO, Christoforou N, Willard VP, Sun H, Sanchez-Adams J, Leong KW, et al. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012;109:19172–7.

Duval E, Leclercq S, Elissalde JM, Demoor M, Galera P, Bouredi K. Hypoxia-inducible factor alpha inhibits the fibroblast-like markers type I and type III collagen during hypoxia-induced chondrocyte redifferentiation: hypoxia not only induces type II collagen and aggrecan, but it also inhibits type I and type III collagen in the hypoxia-inducible factor alpha-dependent reprogramming of chondrocytes. Arthritis Rheum. 2009;60:3038–48.

Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol. 2011;13:215–22.

Elissalde J, Ferran A, Hwang S, Varghese S, Zhang Z. The role of biomaterials in stem cell differentiation: applications in the musculoskeletal system. Stem Cells Dev. 2006;15:295–303.

EMA. ChondroCelect: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins 2014.

Erggelet C, Mandelbaum BR. Principles of cartilage repair: Springer Science & Business Media; 2008.
human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269–75.

Hynes K, Menicanin D, Mrozik K, Grontos S, Bartold PM. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. Stem Cells Dev. 2013;23:1084–96.

Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010;142:375–86.

James D, Levine AJ, Besser D, Hemmati-Brivanlou A. Juncker JP, Sommar P, Skog M, Johnson H, Kratz G. Adipogenic, cartilage differentiation and in vivo repair of osteochondral defect with human induced iPS cells. Nat Methods. 2010;7:197.

Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nature reviews. Mol Cell Biol. 2011;12:79–89.

Junker JP, Sommar P, Skog M, Johnson H, Kratz G. Adipogenic, chondrogenic and osteogenic differentiation of clonally derived human dermal fibroblasts. Cells Tissues Organs. 2010;191:105–18.

Kalpakci KN, Brown WE, Hu JC, Athanasiou KA. Cartilage tissue engineering using dermis isolated adult stem cells: the use of hyaloxia during expansion versus chondrogenic differentiation. PLoS One. 2014;9:e98570.

Kang R, Zhou Y, Tan S, Zhou G, Aagaard L, Xie L, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Stem Cell Res Ther. 2015;6:144.

Kaniehia M, Ferguson D, Prendergast PJ, Campbell VA. Hypoxia promotes chondrogenesis in rat mesenchymal stem cells: a role for AKT and hypoxia-inducible factor (HIF)-1alpha. J Cell Physiol. 2008;216:708–15.

Kim D, Kim C-H, Moon J-I, Chung Y-G, Chang M-Y, Han B-S, et al. Generation of human induced pluripotent stem cells by defined factors. Cell. 2010;142:375–86.

Ko JY, Kim KI, Park S, Im GI. In vitro chondrogenesis and in vivo repair of osteochondral defect with human induced pluripotent stem cells. Biomaterials. 2014;35:3571–81.

Koyama E, Shibukawa Y, Nagayama M, Sugito H, Young B, Yuasa T, et al. A distinct cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse limb skeletogenesis. Dev Biol. 2008;316:62–73.

Ladewig J, Koch P, Brustle O. Leveling Waddington: the emergence of direct programming and the loss of cell fate hierarchies. Nature reviews. Mol Cell Biol. 2013;14:2285–32.

Leung VY, Gao B, Leung KK, Melhadg IO, Wynn SL, Au TY, et al. SOX9 governs differentiation stage-specific gene expression in growth plate chondrocytes via directconcomitant transactivation and repression. PLoS Genet. 2011;7:e1002356.

Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010;7:51–63.

Li HY, Chien Y, Chen YJ, Chen SF, Chang YL, Chiang CH, et al. Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials. 2011a;32:5994–6005.

Li Y, Zhang Q, Yin X, Yang W, Du Y, Hou P, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res. 2011b;21:196–204.

Liao J, Hu N, Zhou N, Lin L, Zhao C, Yi S, et al. Sox9 potentiates BMP2-induced chondrogenic differentiation and inhibits BMP2-induced osteogenic differentiation. PLoS One. 2014;9:e89025.

Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009;30:204–13.

Lu XM, Deng LF, Yang QM. Progress on the related mechanism in the development of bone and joint. Yi chuan = Hereditas. 2004;26:231–4.

Lubis AM, Lubis VK. Adult bone marrow stem cells in cartilage therapy. Acta Med Indones. 2012;44:62–8.

Luni C, Giulitti S, Serena E, Ferrari L, Zambon A, Gagliano O, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–52.

Luyten FP, Hascall VC, Nisssley SP, Morales TL, Reddi AH. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys. 1988;267:416–25.

Ma B, Leijten JC, Wu L, Kip M, van Blitterswijk CA, Post JN, et al. Gene expression profiling of dedifferentiated human articular chondrocytes in monolayer culture. Osteoarthritis Cartil. 2013a;21:599–603.

Ma T, Xie M, Laurent T, Ding S. Progress in the reprogramming of somatic cells. Circ Res. 2013b;112:562–74.

Maekawa M, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, Ichisaka T, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature. 2011;474:225–9.

Mehlhorn AT, Niemeyer P, Kaschke K, Muller L, Finkenzzeller G, Hartl D, et al. Differential effects of BMP-2 and TGF-beta1 on chondrogenic differentiation of adipose derived stem cells. Cell Prolif. 2007;40:809–23.

Mizuno S, Glowacki J. Chondroinduction of human dermal fibroblasts by demineralized bone in three-dimensional culture. Exp Cell Res. 1996;227:89–97.

Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A. 2010;107:14152–7.

Nam BM, Kim BY, Jo YH, Lee S, Nemoen JG, Yang W, et al. Effect of cryopreservation and cell passage number on cell preparations destined for autologous chondrocyte transplantation. Transplant Proc. 2014;46:1145–9.

Nejadnik H, Diecke S, Lenkov OD, Chapelin F, Donig J, Tong X, et al. Improved approach for chondrogenic differentiation of human induced pluripotent stem cells. Stem Cell Rev. 2015;11:242–53.
Nie B, Wang H, Laurent T, Ding S. Cellular reprogramming: a small molecule perspective. Curr Opin Cell Biol. 2012;24:784–92.

Niwa H. How is pluripotency determined and maintained? Development (Cambridge, England). 2007;134:635–46.

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Meth. 2011;8:409–12.

Oldershaw RA, Baxter MA, Lowe ET, Bates N, Grady LM, Soncin F, et al. Directed differentiation of human embryonic stem cells toward chondrocytes. Nat Biotechnol. 2010;28:1187–94.

Oldershaw RA. Cell sources for the regeneration of articular cartilage: the past, the horizon and the future. Int J Exp Pathol. 2012;93:389–400.

Osada R, Ohshima H, Ishihara H, Yudoh K, Sakai K, Matsui H, et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res. 1996;14:690–9.

Outani H, Okada M, Hiramatsu K, Yoshikawa H, Tsumaki N. Induction of chondrogenic cells from dermal fibroblast culture by defined factors does not involve a pluripotent state. Biochem Biophys Res Commun. 2011;411:607–12.

Outani H, Okada M, Yamashita A, Nakagawa K, Yoshikawa H, Tsumaki N. Direct induction of chondrogenic cells from human dermal fibroblast culture by defined factors. PLoS One. 2013;8:e77365.

Pan Q, Wu Y, Lin T, Yao H, Yang Z, Gao G, et al. Bone morphogenetic protein-2 induces chromatin remodeling and modification at the proximal promoter of Sox9 gene. Biochem Biophys Res Commun. 2009;379:356–61.

Pelttari K, Steck E, Richter W. The use of mesenchymal stem cells for chondrogenesis. Injury. 2008;39(Suppl 1):S58–65.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult mesenchymal stem cells. Science (New York, NY). 1999;284:143–7.

Pourmaa B, Khaloughi K, Saledkhe GH, Totonchi M, Shahbazi E, Baharvand H. Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells. Stem Cells (Dayton, Ohio). 2011;29:1933–41.

Provot S, KempFH, Murtaugh LC, Chung U-i, Kim D-W, Chyung J, et al. Nkx3.2/Bapx1 acts as a negative regulator of chondrocyte maturation. Development (Cambridge, England). 2006;133:651–62.

Rackham OH, Firas J, Fang H, Oates ME, Holmes ML, Knaupp AS, et al. A predictive computational framework for direct reprogramming between human cell types. Nat Genet. 2016;48:331–5.

Rao MS, Malik N. Assessing iPSC reprogramming methods for their suitability in translational medicine. J Cell Biochem. 2012;113:3061–8.

Robins JC, Akeno N, Mukherjee A, Dalal RR, Aronow BJ, Koopman P, et al. Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9. Bone. 2005;37:313–22.

Sancho-Martinez I, Baek SH, Izpisua Belmonte JC. Lineage conversion methodologies meet the reprogramming toolbox. Nat Cell Biol. 2012;14:892–9.

Schulze-Tanzil G, de Souza P, Villegas Castrejon H, John T, Merker H-J, Scheid A, et al. Redifferentiation of dedifferentiated human chondrocytes in high-density cultures. Cell Tissue Res. 2002;308:371–9.

Sebban S, Buganim Y. Nuclear reprogramming by defined factors: quantity versus quality. Trends Cell Biol. 2016;26:65–75.

Singh M, Pierpoint M, Mikos AG, Kasper FK. Chondrogenic differentiation of neonatal human dermal fibroblasts encapsulated in alginate beads with hydrostatic compression under hypoxic conditions in the presence of bone morphogenetic protein-2. J Biomed Mater Res A. 2011;98:412–24.

Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. Sports Health. 2009;1:461–8.

Su J-b, D-q P, B-m Q. Roles of small molecules in somatic cell reprogramming. Acta Pharmacol Sin. 2013;34:719–24.

Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynick R, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol. 2011;29:443–8.

Sullivan GJ, Bai Y, Fletcher J, Wilmut I. Induced pluripotent stem cells: epigenetic memories and practical implications. Mol Hum Reprod. 2010;16:880–5.

Takahashi K. Cellular reprogramming—lowering gravity on Waddington’s epigenetic landscape. J Cell Sci. 2012;125:2553–60.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.

Takahashi K, Tanabe K, Ohmuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.

Tam WL, O DF, Hiramatsu K, Tsumaki N, Luyten FP, Roberts SJ. Sox9 reprogrammed dermal fibroblasts undergo hypertrophic differentiation in vitro and trigger endochondral ossification in vivo. Cell Reprogram. 2014;16:29–39.

Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell. 1979;17:771–9.

Teng HF, Li PN, Hou DR, Liu SW, Lin CT, Loo MR, et al. Valproic acid enhances Oct4 promoter activity through PI3K/Akt/mTOR pathway activated nuclear receptors. Mol Cell Endocrinol. 2014;383:147–58.

Teramura T, Onodera Y, Mihara T, Hosoi Y, Hamanishi C, Fukuda K. Induction of mesenchymal progenitor cells with chondrogenic property from mouse-induced pluripotent stem cells. Cell Reprogram. 2010;12:249–61.

Trice ME, Bugbee WD, Greenwald AS, Heim CS. Articular cartilage restoration: a review of currently available methods. 2010.

Tsumaki N, Okada M, Yamashita A. iPSC cell technologies and their suitability in translational medicine. Bone. 2015;70:48–54.

Turner M, Leslie S, Martin Nicholas G, Peschanski M, Rao M, Taylor Craig J, et al. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013;13:382–4.

Umeda K, Zhao J, Simmons P, Stanley E, Elefanty A, Nakayama N. Human chondrogenic paraxial mesoderm, directed specification and prospective isolation from pluripotent stem cells. Sci Rep. 2012;2:455.
Verma A, Verma N. Induced pluripotent stem cells and promises of neuroregenerative medicine. Neurol India. 2011;59:555.

Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463:1035–41.

Wa Q, Gao M, Dai X, Yu T, Zhou Z, Xu D, et al. Induction of chondrogenic differentiation of mouse embryonic mesenchymal stem cells through an in vitro pellet model. Cell Biol Int. 2015;39:657–65.

Waddington CH. Canalization of development and the inheritance of acquired characters. Nature. 1942;150:563–5.

Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X, et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 2011;9:575–87.

Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, Lassar AB, et al. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U S A. 1989;86:5434–8.

Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell. 2008;2:10–2.

Woods A, Wang G, Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem. 2005;280:11626–34.

Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature. 2009;460:49–52.

Yamashita A, Morioka M, Yahara Y, Okada M, Kobayashi T, Kuriyama S, et al. Generation of scaffoldless hyaline cartilaginous tissue from human iPSCs. Stem Cell Rep. 2015;4:404–18.

Yang Z, Sui L, Toh WS, Lee EH, Cao T. Stage-dependent effect of TGF-beta1 on chondrogenic differentiation of human embryonic stem cells. Stem Cells Dev. 2009;18:929–40.

Yang S-L, Harnish E, Leeuw T, Dietz U, Batchelder E, Wright PS, et al. Compound screening platform using human induced pluripotent stem cells to identify small molecules that promote chondrogenesis. Protein Cell. 2012;3:934–42.

Yates KE, Forbes RL, Glowacki J. New chondrocyte genes discovered by representational difference analysis of chondroinduced human fibroblasts. Cells Tissues Organs. 2004;176:41–53.

Yin S, Cen L, Wang C, Zhao G, Sun J, Liu W, et al. Chondrogenic transdifferentiation of human dermal fibroblasts stimulated with cartilage-derived morphogenetic protein 1. Tissue Eng A. 2010;16:1633–43.

Yoon BS, Lyons KM. Multiple functions of BMPs in chondrogenesis. J Cell Biochem. 2004;93:93–103.

Yoon HJ, Kim SB, Somaiya D, Noh MJ, Choi KB, Lim CL, et al. Type II collagen and glycosaminoglycan expression induction in primary human chondrocyte by TGF-beta1. BMC Musculoskelet Disord. 2015;16:141.

Zhai Y, Chen X, Yu D, Li T, Cui J, Wang G, et al. Histone deacetylase inhibitor valproic acid promotes the induction of pluripotency in mouse fibroblasts by suppressing reprogramming-induced senescence stress. Exp Cell Res. 2015;337:61–7.

Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells (Dayton, Ohio). 2009;27:2667–74.